• linkedin
  • Increase Font
  • Sharebar

    How kidney Ca management strategies compare


    Axitinib (Inlyta) appears to be well tolerated and effective for the treatment of patients with metastatic RCC who were unsuitable for nephrectomy. The drug appears to have a 3-month longer median progression-free survival than temsirolimus (Torisel).


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available